ArticleMolecular therapy : the journal of the American Society of Gene Therapy2011
Erythropoietin gene-enhanced marrow mesenchymal stromal cells decrease cisplatin-induced kidney injury and improve survival of allogeneic mice.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Preconditioning with StemRegenin 1 enhances human adipose stromal/stem cells proliferation, migration, and protection against antimycin A.Molecular therapy. Methods & clinical development · 2025Article
- Characterization of MSCs expressing islet neogenesis associated protein (INGAP): INGAP secretion and cell survivalHeliyon · 2024Article
- The Beneficial Effects of Mesenchymal Stem Cells in Acute Kidney Injury: A Narrative Review.Current stem cell research & therapy · 2024Review
- Erythropoietin in Glaucoma: From Mechanism to Therapy.International journal of molecular sciences · 2023Review
- Renal hypoxia-HIF-PHD-EPO signaling in transition metal nephrotoxicity: friend or foe?Archives of toxicology · 2022Review
- MicroRNA-146a-5p-modified human umbilical cord mesenchymal stem cells enhance protection against diabetic nephropathy in rats through facilitating M2 macrophage polarization.Stem cell research & therapy · 2022Article
- Human umbilical cord-derived mesenchymal stem cells and human cord blood mononuclear cells protect against cisplatin-induced acute kidney injury in rat models.Experimental and therapeutic medicine · 2020Article
- Mesenchymal Stem Cells as Therapeutic Agents and Novel Carriers for the Delivery of Candidate Genes in Acute Kidney Injury.Stem cells international · 2020Review
- Empowering Mesenchymal Stem Cells for Ocular Degenerative Disorders.International journal of molecular sciences · 2019Review
- Human Peripheral Blood Mononuclear Cells Incubated in Vasculogenic Conditioning Medium Dramatically Improve Ischemia/Reperfusion Acute Kidney Injury in Mice.Cell transplantation · 2018Article
- Immunomodulatory plasticity of mesenchymal stem cells: a potential key to successful solid organ transplantation.Journal of translational medicine · 2018Review
- Erythropoietin facilitates the recruitment of bone marrow mesenchymal stem cells to sites of spinal cord injury.Experimental and therapeutic medicine · 2017Article
- (Mesenchymal) Stem Cell-Based Therapy in Cisplatin-Induced Acute Kidney Injury Animal Model: Risk of Immunogenicity and Tumorigenicity.Stem cells international · 2017Review
- Revisiting the role of erythropoietin for treatment of ocular disorders.Eye (London, England) · 2016Review
- The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy.Stem cell research & therapy · 2015Review
- Mesenchymal stem cells, not conditioned medium, contribute to kidney repair after ischemia-reperfusion injury.Stem cell research & therapy · 2014Article
- Pathophysiology of cisplatin-induced acute kidney injury.BioMed research international · 2014Review
- Administration of BMSCs with muscone in rats with gentamicin-induced AKI improves their therapeutic efficacy.PloS one · 2014Article
- Wnt1 inducible signaling pathway protein 1 (WISP1) blocks neurodegeneration through phosphoinositide 3 kinase/Akt1 and apoptotic mitochondrial signaling involving Bad, Bax, Bim, and Bcl-xL.Current neurovascular research · 2012Article
- PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone marrow-derived mesenchymal stromal cells (MSCs) are promising for regenerative medicine applications, such as for renoprotection and repair in acute kidney injury (AKI). Erythropoietin (Epo) can also exert cytoprotective effects on various tissues including the kidney. We hypothesized that MSCs gene-enhanced to secrete Epo may produce a significant beneficial effect in AKI. Mouse Epo-secreting MSCs were generated, tested in vitro, and then implanted by intraperitoneal injection in allogeneic mice previously administered cisplatin to induce AKI. Epo-MSCs significantly improved survival of implanted mice as compared to controls (67% survival versus 33% with Vehicle only). Also, Epo-MSCs led to significantly better kidney function as shown by lower levels of blood urea nitrogen (72 ± 9.5 mg/dl versus 131 ± 9.20 mg/dl) and creatinine (74 ± 17 µmol/l versus 148±19.4 µmol/l). Recipient mice also showed significantly decreased amylase and alanine aminotransferase blood concentrations. Kidney sections revealed significantly less apoptotic cells and more proliferating cells. Furthermore, PCR revealed the presence of implanted cells in recipient kidneys, with Epo-MSCs leading to significantly increased expression of Epo and of phosphorylated-Akt (Ser473) (P-Akt) in these kidneys. In conclusion, our study demonstrates that Epo gene-enhanced MSCs exert significant tissue protective effects in allogeneic mice with AKI, and supports the potential use of gene-enhanced cells as universal donors in acute injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.